Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Pharma IQ is Pleased to Announce                              Now in it’s 3rd Year Biobanking has welcomed:
The Latest in ...
Pre-Conference Workshops 27 September 2010
WORKSHOP A                                                                  WOR...
Conference Day One 28 September 2010
    08.00 Registration and Coffee                                 ...
Conference Day Two 29 September 2010
08.30 Registration and Coffee                                    12:20 Case Study: Bu...
CD-ROM Sponsor                                                                       Featured Exhibitor

Nexus Biosyste...
Global Biobanking 2O1O                                                                                                    ...
Upcoming SlideShare
Loading in …5

Biobanking 2010 Brochure


Published on

Published in: Education
  • Be the first to comment

  • Be the first to like this

Biobanking 2010 Brochure

  1. 1. Pharma IQ is Pleased to Announce Now in it’s 3rd Year Biobanking has welcomed: The Latest in Europe’s Leading Over 200 Attendees from Commercially Focused Global Over 140 Different Organisations “ In such a topically Biobanking diverse area, IQPC delivered a top class agenda with “ speakers and 2O1O delegates to match Conference: 28th - 29th September 2010 Workshop Day: 27th September 2010 Qiagen Venue: Thistle Marble Arch, London, UK Advancing International R&D Through 17 world-renowned speakers: Effective Sample Management and INTERNATIONAL ADVISORY BOARD: Global Biobanking Harmonisation Peter Riegman, President, ISBER TOP 3 Reasons to attend Europe’s leading industry forum: Björn Dahllöf, Global Biobank Head, AstraZeneca 1. Exclusive access to 17 expert biobanking speakers including 7 must see brand new industry case studies! Aleks Davis, Head of Biological 2. Unparalleled networking opportunities across 3 days Sample Management, Eli Lilly including exclusive evening drinks reception to make new contacts and benchmark with your peers Manuel Morente, Head of Tumour Bank Unit, Spanish National Cancer Centre 3. Join the debate on LinkedIn to be part of the largest industry-focused biobanking event before it even takes place! Glyn Stacey, Director, UK Stem Cell Bank Mark Divers, Head of Biobank, Karolinska Institute Attending Biobanking 2010 will ensure you can: Amelia Wall Warner, Head of Clinical Establish and develop an efficient global biobank network Pharmacogenomics and Clinical Specimen with tips from Björn Dahllöf, Global Biobank Head, AstraZeneca Management, Merck Research Laboratories Recover costs more effectively with insights on making better Andreas Koehler, Global Head Clinical use of available resources from Heather Thorne, KConFab Manager, Peter MacCallum Cancer Centre Pharmacogenetics, Boehringer-Ingelheim Expand your sample collection and operating potential with Laurie Overton, Manager, Fermentation Facility, the latest ISBER and BBMRI plans for future global biobank GlaxoSmithKline harmonisation and standardisation from Peter Riegman and Manuel Morente Arndt Schmitz, Leader of Biobank, Refine the QC of your SOPs to ensure high quality samples for Bayer-Schering identification of new targets for drug discovery and development Gerardo de Pierro, Sample Management research with Aleks Davis, Head of Biological Sample and Logistics Manager, Novartis Management, Eli Lilly Improve drug efficacy by integrating biobanking into industry Chris Womack, Principal Clinical biomarker research to identify new biomarkers from your samples: Histopathologist, AstraZeneca discussion led by Arndt Schmitz, Biobank Leader, Bayer-Schering Rivka Ravid, Senior Scientist and Advisor, Royal Dutch Academy of Sciences 4 Exclusive Interactive Pre-Conference Workshops: A: Technology Spotlight: Real Solutions for Biobanking Gerry Thomas, Professor of Molecular B: Optimising Your Operating Efficiency with an Effective IT Infrastructure Pathology, Imperial College London C: Potentials and Pitfalls in Establishing a Global Network to Identify Aoife McDermott, Senior Medical Scientist, Biospecimens for Research Adelaide and Meath Hospital D: Building an Internal Pharma Biobank to support Drug Discovery and Development Heather Thorne, National kConFab Manager, See inside for more details and package discounts… Peter MacCallum Cancer Centre Jane Rogan, Biobank Business Manager, Visit: Manchester Cancer Research Centre Sponsors & +44 (0)20 7368 9300 +44 (0)20 7368 9301 Exhibitors
  2. 2. Pre-Conference Workshops 27 September 2010 WORKSHOP A WORKSHOP B 09:00 - 12:00 12:15 - 15:15 Technology Spotlight: Real Solutions for Biobanking Optimising Your Operating Efficiency with an Effective IT Infrastructure Technology within biobanking can be a successful solution to improve the operating efficiency of your biobank, with some of the most successful Many new biobanks and those wishing to expand their capacity and technologies including sample tracking and tracing, automation, cryo service ability rapidly and effectively have identified that one of the and ambient storage, integrated IT solutions and many more. Key topics key requirements is having an excellent, fully-integrated, flexible and for this workshop will include: customisable IT solution at the core of their system. In this interactive • Existing technologies in the market for sample tracking technologies session: • Existing technologies in the market for specimen storage • Discover how a smart IT solution can vastly increase the efficiency of • Which existing technologies are most effective and why your biobank • What are the next steps from all parties to ensure that these • Improve the quality of your services with effective sample management technologies do not become obsolete as quickly as others in the past • Widen your client base by providing more information about samples and in greater detail Please visit for more details. • Manage all your sample data in one simple, easy-to-use database Please visit for more details. WORKSHOP C WORKSHOP D 15:30 - 18:30 18:45 - 21:45 Potentials and Pitfalls in Establishing a Global Building an Internal Pharma Biobank to support Network to Identify Biospecimens for Research Drug Discovery & Development This workshop presents and provides the basic concepts, current and This interactive session allows you to share experiences and discuss future use of a global network aiming at identifying biospecimens for aspects of establishing an efficient internal global biobank. Examples will research. The workshop deals with the following issues: be given from the AstraZeneca Biobank. Topics for discussion include: • Challenges and the difficulties for the rare disease Global community • The use of human tissue for drug discovery & development to obtain sufficient amounts of biospecimens for basic and clinical • Sources, acquisition and external collaborations research • Ethical and regulatory considerations • The need for collaborative and novel approaches • Establishing a global network that facilitates coordination • The use of patient registries to increase procurements of rare disease • Building an internal infrastructure biospecimens • Looking at the challenges ahead • The urgent need for linking every patient registry with a biorepository • The need for global rare disease network to facilitate sharing and Facilitated by: Björn Dahllöf, Global Biobank Head, AstraZeneca collaboration among all stakeholders. Chris Womack, Principal Clinical Histopathologist, AstraZeneca Facilitated by: Rivka Ravid, Senior Scientist and Advisor, Royal Dutch Björn Dahllöf, Director in “Discovery Enabling Academy of Sciences; Capabilities and Sciences (DECS) / Translational Heather Thorne, National kConFab Manager, Peter MacCallum Cancer Centre Sciences”, is the Global Head of the recently established biobank for human samples in AstraZeneca. He has Rivka Ravid is a Tissue/Bio banker and a a PhD in genetics from the University of Gothenburg neuroscientist. She is one of the pioneers of the (1986) and received post-doctoral training in cell biology European Brain Banking Network (EBBN+BNE) and at the Ludwig Institute for Cancer Research (LICR; Stockholm Branch, since 2001 has been the Director of the Netherlands 1988-1992). In 1993 he joined Pharmacia in Lund Sweden (later Pfizer) to Brain Bank and a Scientific Project leader at the work on chemotherapy for prostate cancer. 1994 he took up a position in Netherlands Institute for Brain Research, Amsterdam Discovery at Astra, Mölndal, Sweden (later AstraZeneca) working in the and the Brain Net Europe. Presently she is busy with areas of diabetes, metabolic syndrome and applied proteomics. During setting up new biobanks and enhancing public awareness of the need recent years he has focussed his efforts on the translational area, - for human specimens for research. Rivka Ravid is also an expert on biomarkers, target validation using human material, molecular medicine, the legal/ethical issues in Bio banking and pioneered the setting up and was the Director of Discovery Medicine for the Cardiovascular and of an international Ethical Code of Conduct. She specialises in CNS Gastrointestinal Research Area in AstraZeneca 2006-2008. Since 2008 he biomarker research for early diagnostics, based on specimens from is leading the AstraZeneca biobank of human samples, covering 10 R&D living patients as well as rapid post-mortem autopsies. sites globally. The remit of the global biobank is to secure legal & ethical compliance, harmonise processes & tools, provide biobanking facilities, give input to policies and processes, share best practice and facilitate exploitation of human samples globally. INTERNATIONAL ADVISORY PANEL Peter Riegman, Björn Dahllöf, Aleks Davis, President, Global Biobank Head, Head of Biological Sample ISBER AstraZeneca Management, Eli Lilly +44 (0)20 7368 9300 +44 (0)20 7368 9301
  3. 3. Conference Day One 28 September 2010 08.00 Registration and Coffee 12:20 Human Tissue in Oncology Research at AstraZeneca: Enabling Decision Making 09.00 Pharma IQ Welcome and Chairperson’s Opening • Securing a supply of human tissue for research and Address establishing a reliable network • Adhering to legal, ethical and biosafety requirements INCREASING OPERATIONAL EFFICIENCY AND • Ensuring sample quality • Human tissue research enabling decision making: PRODUCTIVITY THROUGH EFFECTIVE COMMUNICATION practical examples from discovery, early and late AND COLLABORATION clinical development Chris Womack, Principal Clinical Histopathologist, 09:10 KEYNOTE: Global Biobank Harmonisation: Practical AstraZeneca Reality or Wishful Thinking? • Facilitating the search for samples for multi-centre 13:00 Networking Lunch Break cancer translational research in Europe • Assessing the need for multi-centre research to allow 14:10 Biobanking Within the Walls of Pharma: An Eli Lilly sample and data exchangeability Case Study • Discussing QA and QC in today’s healthcare research • Reviewing the Combined Specimen Bank, an biobanking industry-designed biobank and IT solution • Evaluating internal vs external quality assurance • Discussing the challenges and potential solutions for (EQA) sample collection • Predicting the effects of EQA on overall biobank • Meeting the needs of discovery research to validate quality and credibility targets in human models earlier • Standardisation in tissue collections; locally and • Assessing when to partner with external sample across networks resources Peter Riegman, President, ISBER • Looking to the future: what’s next for the Lilly Biobank? 09:50 Developing International Biobank Networking: When Aleks Davis, Head of Biological Sample Management, 1+1 is Greater Than 2 Eli Lilly • Discussing the need for and scientific value of biobank networks 14:50 Integrating Biobanking into Industry Biomarker • Assessing the designs and common challenges with a Research to Improve Translational Medicine biobank network • Building up dry ice logistic processes to have a • Identifying both the potential basic services and reliable, convenient, robust and affordable solution practical limitations of a network • Developing personalised medicine together with • Case study: the Spanish model for biobank clinicians and today’s standard of care networking • Accepting clinical realities in order to minimise risks Manuel Morente, Head of Tumour Bank Unit, Spanish in clinical sample and data collection National Cancer Centre • Anticipating the perspectives of both colleagues and the management to meet tomorrow’s requirements 10:30 Networking Coffee Break Arndt Schmitz, Leader of Biobank, Bayer-Schering 11:00 Using Available Resources in Biobank-Industry 15:30 Networking Coffee Break Partnerships to Improve Your Cost Recovery • Reviewing the resources biobanks have available to 15:50 Ensuring Sample Quality and Integrity to Improve CNS- them Biomarker Drug Discovery and Development • Discussing how these resources can be utilised to • Reviewing the Standard Operating Procedures their full advantage for specimen procurement, management, • Highlighting how biobanks can help the preparation, dissemination and storage pharmaceutical industry • Assessing the quality of the disseminated samples • 2 Case Studies: a National and State partnership with • Producing a code of conduct for the social, ethical and the pharmaceutical industry legal considerations Heather Thorne, kConFab Manager, • Ensuring you have the right IT infrastructure, Peter MacCallum Cancer Centre including proper electronic tracking systems • Discussing safety procedures MAINTAINING HIGH STANDARDS OF QUALITY AND • Successful case studies of biomarker-biobank alliances Rivka Ravid, Senior Scientist and Advisor, Royal Dutch INTEGRATING BIOBANKING INTO RESEARCH TO Academy of Sciences ADVANCE INTERNATIONAL DRUG DEVELOPMENT RESEARCH AND ENABLE DECISION MAKING 16:30 PANEL DISCUSSION: The Variations and Flexibility of Informed Consent 11:40 From Patient to RNA: a Hospital’s Experience of How a • What does informed consent actually cover? Biobank Can Help Research • How does it vary between countries? • Collecting consistent and high-quality specimens • How can we handle unexpected situations under • Storing tissues with intact morphology, proteins, DNA informed consent? and RNA for use in research and diagnostics • Is it possible to create an international standardised • Ensuring sample quality through specific initial form? collection SOPs Panelists: • Collecting ‘fresh’ frozen tissues for use as Peter Riegman, President, ISBER high-quality RNA sources in research studies Andreas Koehler, Global Head Clinical • Avoiding RNAse contamination in samples to ensure Pharmacogenetics, Boehringer-Ingelheim preservation of specimen Chris Womack, Principal Clinical Histopathologist, Aoife McDermott, Senior Medical Scientist, Adelaide AstraZeneca and Meath Hospital 17:10 Chairperson’s Closing Remarks and Close of Day One 17:30-18:30 EVENING DRINKS RECEPTION +44 (0)20 7368 9300 +44 (0)20 7368 9301
  4. 4. Conference Day Two 29 September 2010 08.30 Registration and Coffee 12:20 Case Study: Building a Large-Scale National Biobank for Sweden 09.00 Pharma IQ Welcome and Chairperson’s Opening • The opportunity: diverse projects in a nation with Address strengths in population studies and health registries Peter Riegman, President, ISBER • Creating a smart overall plan for a large-scale biobank • Progressive build-up of capability and capacity: input, storage, retrieval SUPPORTING DRUG DEVELOPMENT AND NAVIGATING • Teething troubles: converting problems into opportunities REGULATIONS TO IMPROVE THE QUALITY OF YOUR • Reviewing the progress so far • Evaluating outcomes: how good is a biobank? How big SERVICES AND SAMPLE should it be? Mark Divers, Head of Biobank, Karolinska Institute 09:10 Biological Archiving in Discovery Research to Support Drug Development 13:00 Networking Lunch Break • Discussing the types of reagents and information that should be archived SUPPORTING DRUG DEVELOPMENT AND NAVIGATING • Ensuring data integrity and quality assurance REGULATIONS TO IMPROVE THE QUALITY OF YOUR • Managing sample registration and distribution SERVICES AND SAMPLE • Establishing secure storage and inventory management 14:10 Implementing Informatics in a Multi-Centre Biobank to Laurie Overton, Manager, Fermentation Facility, Improve Operating Efficiency GlaxoSmithKline • A brief introduction to the MCRC biobank • Identifying the need for effective informatics 09:50 Collection of Future Use Genomic Specimens in Global • Assessing the problems and solutions Clinical Trials: Navigating Regulations, Requests for • Labelling and bar-coding biological samples Changes in Sample Permissions and Tracking Final • Implementing a commercial LIMS package Approved Sample Permissions • Discussing future developments and improvements • Utilising future use specimens for pharmaceutical Jane Rogan, Biobank Business Manager, Manchester companies Cancer Research Centre • Reviewing pharmaceutical industry sampling practices as published by the Industry 14:50 Staying on Track: Efficient Sample Management to Pharmacogenomics Working Group (I-PWG) Improve Biobank Operating Efficiency • Identifying variation in sample permissions allowed • Receiving, confirming and tracking new samples from global Ethics Committees, IRBs and Health • Maintaining high quality standards for GLP samples Authorities • Using a barcode system to enter new clinical samples • Discussing issues with approvals to collect specimens • Systematically arranging biospecimens for storage • Tracking sample permissions for global clinical trials • Sample logistics: internal and international shipping Amelia Wall Warner, Head of Clinical of biological samples, analytical compounds and materials Pharmacogenomics and Clinical Specimen • Ensuring correct disposal of biological samples Management, Merck Research Laboratories Gerardo de Pierro, Sample Management and Logistics Manager, Novartis 10:30 Networking Coffee Break 15:30 Networking Coffee Break BIOBANK CASE STUDIES: DEVELOPING AN EFFECTIVE INTERNATIONAL BIOBANK AND ACHIEVING YOUR FULL 15:50 Assessing Specimen Fitness for Purpose and Safe Limits for Research POTENTIAL OPERATING EFFICIENCY • Identifying pre-analytical variables affectingRNA from frozen tissue, DNA from FFPE tissue and proteins 11:00 Case Study: Developing and Maintaining the • Discussing the practical minimum level of QA for AstraZeneca Biobank tissue samples obtained from patients • Assessing the challenges, changes and developments • Molecular-friendly fixatives: can we combine good over the last 12 months morphology with the preservation of nucleic acids? • Supporting drug discovery and development with • Maximising the use of samples by making derivatives human biological samples from tissue and supplying only what is necessary • Reviewing the AstraZeneca Human Biological Sample Gerry Thomas, Professor of Molecular Pathology, Policy 2010 Imperial College London • Discussing the ethical standards and governance • Consolidating infrastructure to support business 16:40 The Significance of Stem Cells and Cell Therapy for Global Biobanking: from Specialty to Necessity needs Recent exciting developments in stem cell research • Considering internal vs. external biobanking with build on several decades of research into accessibility, control and costs in mind haematopoietic stem cells and their clinical Björn Dahllöf, Global Biobank Head, AstraZeneca application in the form of bone marrow and cord blood. New developments in therapies often focus on these 11:40 Developing Global DNA Banking to Support Drug stem cells types which offer resources that can deliver Development human stem cells much more readily into laboratory • Setting up an automated DNA banking facility and work while avoiding repeated consent and the licenses efficient sample management required for storing human tissue. Using the UK Stem • Discussing sample and data collection across global Cell Bank as an example, this presentation will address clinical trials a range of the key scientific and practical challenges • Assessing IT solutions to support DNA banking and stem cells present for the biobanking community. sample analysis • Discussing the broad impacts of stem cells for research • Evaluating lessons learned from PGx informed • Analysing what they mean for the future of biobanking consent and data protection • Understanding the practical and ethical changes and • Understanding the value and use of banked samples their potential impact on biobanking Andreas Koehler, Global Head Clinical • Considering the challenges of mass stem cell storage and when they must be addressed Pharmacogenetics, Boehringer-Ingelheim Glyn Stacey, Director, UK Stem Cell Bank 17:10 Chairperson’s Closing Remarks and Close of Day One +44 (0)20 7368 9300 +44 (0)20 7368 9301
  5. 5. CD-ROM Sponsor Featured Exhibitor Nexus Biosystems provides high-integrity solutions for demanding Life Liconic AG is a major manufacturer and supplier of automated storage Science applications. From Sample Storage to Sample Analysis, Nexus systems and environmental chambers for small and large scale sample provides high-performance products and services to high-value discovery storage. In 2009, Liconic successfully installed their first -80°C Storage laboratories. Nexus provides the Universal Store line of Automated Biological System and have since installed several further systems which can and Chemical Compound Sample Storage, for highly-modular and expandable offer capacities ranging from 1 million to 10 million samples. This offers systems from -80°C, -20°C and ambient environments. Nexus manufactures an exceptionally high degree of reliability in this relatively new field of and sells its’ XPeel Automated Seal-Removal Systems enabling highly- automated -80°C storage systems. Liconic provides solutions that eliminate automated systems to run unattended. Nexus markets the Aurora Microplate repetitive tasks, by automating what have previously been manual processes, Products for sensitive fluorescence and cellular-imaging applications in the implementing effective sample management, storage solutions. world’s leading assay development and screening settings. Liconic UK Ltd Phone: 0044 (0) 1618752542 European Office: Phone: +49 8171 380711 Warren Bruce Court Fax: 0044 (0) 1618752540 NEXUS Biosystems GmbH Fax: +49 8171 380712 Warren Bruce Road Mobile: 0044 (0) 7500214061 Alpenstrasse 76 Sales: Trafford Park Email: 82538 Geretsried General Inquiry: Germany Media Partners Who Should Attend? Senior Vice President, Vice President, Executive Director, Director, Associate Director, Head and Manager from: • Independent Biobanks Sponsorship & Exhibition Opportunities • Pharmaceutical • Biotech Maximise Your Involvement: Sponsorship and Exhibition Opportunities • Medical Research Institute The Pharma IQ Global Biobanking 2010 conference will be the perfect • Academia platform for service providers to meet senior-level decision makers in the pharmaceutical/biopharmaceutical industry implementing specific • Related government officials storage, IT, automation, CRO, sample processing, sample analysis, coding and tracking solutions and services. Contact Pharma IQ to discuss In the following departments: how to position your company in front of our participants who are keen to learn more about today’s technologies and services including decision • Research & Development makers and Heads of biobanks, biorepositories, tissue banks, DNA banks • Biobanking and sample management from industry, research institutes, hospitals • Biorepository and academia. • Biological Sample Management To profile your company at this event please contact Gal Cohen on • Biosample Management +44 207 368 9300 or email • Pharmacogenomics • Pathology About Pharma IQ • Genomics • Translational Medicine • Personalised Medicine • Lab Management Become a member of Pharma IQ and receive complimentary access to resources that will keep you at the forefront of industry change. • Inventory Management You will receive access to our growing library of multi-media presentations • Molecular Technologies from industry leaders, an email newsletter updating you on new content • Biologics Research that has been added, free aggregated news feed from over 1000 global news sources tracking your industry and special member only discounts • Data Privacy/Protection/Security Officers on events. • Quality Control and Quality Management Become a member here: • PI Department Web: Phone: +44 (0) 207 368 9300 +44 (0)20 7368 9300 +44 (0)20 7368 9301
  6. 6. Global Biobanking 2O1O 5 WAYS TO REGISTER Freephone: 0800 652 2363 or +44 (0)20 7368 9300 To speed registration, please provide the priority code located on the mailing label or in the box below. My registration code is: Fax: +44 (0)20 7368 9301 PDFW Please contact our database manager on +44(0) 207 368 9300 or at quoting the registration code above to Post: your booking form to inform us of any changes or to remove your details. IQPC Ltd. Anchor House, 15-19 Britten Street, London SW3 3QL INDUSTRY RATES Packages Register and Pay by Register and Pay by Register and Pay by Standard Price Online: 28th May* 9th July* 13th August* Email: Platinum Package SAVE £600 SAVE £500 SAVE £400 £3495 + VAT Conference + 4 Workshops £2895+ VAT £2995 + VAT £3095 + VAT Gold Package SAVE £500 SAVE £400 SAVE £300 £2996 + VAT Conference + 3 Workshops** £2496 + VAT £2596 + VAT £2696 + VAT Join our Global Biobanking event on Silver Package SAVE £400 SAVE £300 SAVE £200 £2497 + VAT Conference + 2 Workshops** £2097+ VAT £2197 + VAT £2297 + VAT Bronze Package SAVE £300 SAVE £200 SAVE £100 £1998 + VAT Conference + 1 Workshop** £1698+ VAT £1798 + VAT £1898 + VAT Team Discounts* Conference Only SAVE £200 SAVE £100 £1499 + VAT £1499 + VAT £1299+ VAT £1399 + VAT IQPC recognises the value of learning in teams. Groups of 3 or more booking at the same time from the same company receive a 10% ACADEMIC, NON-PROFIT and NATIONAL BIOBANKS RATES discount. 5 or more receive a 15% discount. 7 receive a 20% discount. Register and Pay by Standard Price Only one discount available per person. 28th May Platinum Package Conference + 4 Workshops SAVE £450 £1299 + VAT £1749 + VAT Venue & Accommodation VENUE: Gold Package Conference + 3 Workshops** SAVE £400 £1499 + VAT Thistle Marble Arch £1099 + VAT Bryanston Street, Marble Arch, London W1H 7EH Silver Package Conference + 2 Workshops** SAVE £350 £1249 + VAT Phone: 0871 376 9027 Fax: 0871 376 9127 £899 + VAT ACCOMMODATION: Bronze Package Conference + 1 Workshop** SAVE £300 £999 + VAT For Thistle Marble Arch Tel: +44 (0)871 376 9027 select option 1, £699 + VAT or email: . Always Conference Only SAVE £250 £749 + VAT quote promotional code GA1. Prices from £130 + vat including £499 + VAT breakfast. Or for a further selection of London. hotels search *To qualify for discounts, payments must be received by the early bird registration deadline. Early booking discounts are not valid in conjunction with any other offer. UK VAT is charged at 17.5%. VAT Registration # GB 799225967 ** Please select your choice of workshop(s) A 6B6C6D6 Free Online Resources To claim a variety of articles, podcasts and other free resources please Delegate Details visit Please photocopy for each additional delegate 6 Mr 6 Mrs 6 Miss 6 Ms 6 Dr 6 Other Digital Conference On CD-ROM First Name Family Name A digital version of the conference proceedings, including all presentations, is available to buy. Job Title 6 I cannot attend the event, please send me the CD Rom priced at Tel No. £599 plus VAT Email Recent digital conferences available - £599 plus VAT each 6 Yes I would like to receive information about products and services via email 6 Biobanking 2009 Organisation 6 Compound Management 2009 Nature of business 6 Disposables for Biomanufacturing 2009 6 Cool Chain Europe 2010 Address Postcode Country Please send me conference materials indicated above. Telephone Fax I have filled out credit card details below Approving Manager For further information Name of person completing form if different from delegate: Please call: 0207 368 9300 or email: Signature I agree to IQPC’s cancellation, substitution and payment terms Terms and Conditions Special dietary requirements: 6 Vegetarian 6 Non-dairy 6 Other (please specify) Please read the information listed below as each booking is subject to IQPC Ltd standard terms and conditions. Return of this email will indicate that you accept these terms. Please indicate if you have already registered by Phone 6 Fax 6 Email 6 Web 6 Payment Terms Upon completion and return of the registration form full payment is required no later than 5 Please note: if you have not received an acknowledgement before the conference, please call us to confirm your booking. business days from the date of invoice. Payment of invoices by means other than by credit card, or purchase order (UK Plc and UK government bodies only) will be subject to a £49 (plus VAT) per delegate processing fee. Payment must be received prior to the conference date. We reserve the right to refuse admission to the confer- Payment Method ence if payment has not been received. IQPC Cancellation, Postponement and Substitution Policy You may substitute delegates at any time by providing reasonable advance notice to IQPC. For any cancellations received in writing not less than eight (8) Total price for your Organisation: (Add total of all individuals attending): days prior to the conference, you will receive a 90% credit to be used at another IQPC conference which must occur within one year from the date of issuance of such credit. An administration fee of 10% of the contract fee Card Number: VISA 6 M/C 6 AMEX 6 will be retained by IQPC for all permitted cancellations. No credit will be issued for any cancellations occurring within seven (7) days (inclusive) of the conference. 6666666666666666 In the event that IQPC cancels an event for any reason, you will receive a credit for 100% of the contract fee paid. You may use this credit for another IQPC event to be mutually agreed with IQPC, which must occur within one year from the date of cancellation. Exp. Date: 6 6 6 6 Sec: 6 6 6 6 Conference code 13647.003 In the event that IQPC postpones an event for any reason and the delegate is unable or unwilling to attend in on the rescheduled date, you will receive a credit for 100% of the contract fee paid. You may use this credit for another IQPC event to be mutually agreed with IQPC, which must occur within one year from the date of Name On Card: Signature: postponement. Except as specified above, no credits will be issued for cancellations. There are no refunds given under any circumstances. Billing Address (if different from below): IQPC is not responsible for any loss or damage as a result of a substitution, alteration or cancellation/postpone- ment of an event. IQPC shall assume no liability whatsoever in the event this conference is cancelled, resched- City/County/Postcode Cheque enclosed for: £ (Made payable to IQPC Ltd.) uled or postponed due to a fortuitous event, Act of God, unforeseen occurrence or any other event that renders performance of this conference impracticable, illegal or impossible. For purposes of this clause, a fortuitous event shall include, but not be limited to: war, fire, labour strike, extreme weather or other emergency. Please note that while speakers and topics were confirmed at the time of publishing, circumstances beyond the (Please quote 13647.003 with remittance advice) control of the organizers may necessitate substitutions, alterations or cancellations of the speakers and/or topics. As such, IQPC reserves the right to alter or modify the advertised speakers and/or topics if necessary without any IQPC Bank Details: HSBC Bank, 67 George Street, Richmond Surrey, TW9 1HG. Sort Code: 40-38-18 Account No: 51304143 Swift liability to you whatsoever. Any substitutions or alterations will be updated on our web page as soon as possible. Code: MIDLGB2112V IBAN Code: GB59MIDL40381851304143 Account Name: International Quality & Productivity Centre Ltd. Discounts All ‘Early Bird’ Discounts require payment at time of registration and before the cut-off date in order to receive any discount. Any discounts offered whether by IQPC (including team discounts) must also require payment at the time of registration. All discount offers cannot be combined with any other offer PAYMENT MUST BE RECEIVED PRIOR TO THE CONFERENCE